Although T-DM1 showed promising antitumor effects in preclinical models of HER2 overexpressing bladder cancers [83], the multi-histology phase II, basket trial of TDM-1 in patients with HER2 amplified cancers failed to demonstrate a significant activity of this drug in patients with mUC.. This evidence concerns the gene ERBB2 and urinary bladder cancer.